The research of RGD-conjugated PLA-PLL nanoparticles carriers on targeted delivery to tumor
The development of a more precise targeted delivery system is critical for the advancement of cancer chemotherapy. In this study, we evaluated the effects of RGD-conjugated poly (lactic acid-co-lysine)-(Arginine-Glycine-Aspartic) nanoparticles (PLA -PLL-RGD NPs) on targeted drug delivery for BACP-37 breast cancer. PLA-PLL-RGD NPs were prepared by using the emulsion method. A subsequent MTT assay indicated that the NPs were non-toxic. In vitro, the results of Confocal Laser Scanning Microscopy (CLSM) and Flow cytometry analyses indicated that the PLA-PLL-RGD NPs can bind more significantly to human umbilical vein endothelial cells (HUVECs) compared with PLA-PLL NPs. In vivo, the results of targeted imaging showed that PLA-PLL-RGD can significantly target to BACP-37 breast cancer. These results showed that PLA-PLL-RGD NPs have the potential to be used as targeted delivery carrier.